Anthem Biosciences Limited · NSE:ANTHEM
Anthem Biosciences — Q1 FY2027 Earnings Presentation
9 slides from Anthem Biosciences's earnings presentation, Jul 21, 2026
Slide 1: Stock exchange cover letter: revised earnings call presentation
Date: July 21, 2026 To, BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Revised Earnings Call Presen
Slide 2: Anthem Biosciences Limited Investor Presentation
Anthem Biosciences Limited Investor Presentation July 21, 2026
Slide 3: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Consolidated Profit & Loss Statement: Q1FY27 vs Q1FY26 vs Q4FY26 Performance
Consolidated Profit & Loss Statement: Q1FY27 vs Q1FY26 vs Q4FY26 Performance Particulars (₹ Mn) Q1FY27 Q1FY26 YoY Q4FY26 QoQ FY26 Revenue from Operations 4,182 5,402 -22.6% 6,109 -31.5% 21,243 CRDMO 3,408 4,527 -24.7% 5,128 -33.5% 17,727 Specialty Ingredients 774 875 -11.5% 981 -21.1% 3,516 Other In
Slide 5: Q1FY27 Consolidated Financial Highlights
Q1FY27 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 5,402 38.1% 39.6% 24.1% 27.1% 4,182 2,143 1,755 1,358 1,199 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 PBT (₹ Mn) and PBT Margins (%age) Net Cash (₹ Mn) Specialty Ingred
Slide 6: Margin profile continues to remain strong for Q1FY27
Margin profile continues to remain strong for Q1FY27 ₹4,182 Mn 39.6% 27.1% Strong Business Q1FY27 Revenues Q1FY27 EBITDA Margin Q1FY27 PAT Margin Performance 14 + 10 425KL 142KL Robust Technology Commercial + Custom Synthesis Capacity Fermentation Capacity and Infrastructure Late Stage (Phase III) M
Slide 7: Financial Highlights: Q1FY27
Financial Highlights: Q1FY27 Quarter Performance: Consolidated Revenue from Operations was ₹4,182 Mn for the quarter CRDMO business delivered ₹3,408 Mn revenues Specialty Ingredients delivered ₹774 Mn revenues EBITDA was ₹1,755 Mn, with EBITDA margins at 39.6% PAT (Profit After Tax) was ₹1
Slide 8: Message from Chairman, MD and CEO
Message from Chairman, MD and CEO “Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum. We remain fi
Slide 9: Thank You
Thank You Anthem Biosciences Limited NeoAnthem Lifesciences Private Limited Unit I: No.49, F1 &F2, Canara Bank Road, Unit III: 313-P,314-P, 318-P, Harohalli Bommasandra Industrial Area Phase 1, Industrial Area, Phase II, Bommasandra, Bangalore, 560 099, India Kanakapura Taluk, Ramnagar District, Har